Nevertheless, the substantial progress that has been made in this field will make it possible to allow in vivo detection of tau in AD and thus the reassessment of inclusion- and outcome criteria of clinical trials aiming to intervene at tau-aggregates. This evidence concerns the gene MAPT and Alzheimer disease.